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Abstract
The spectrum of activity of vitamin D goes beyond calcium and bone homeostasis, and growing evidence suggests that vitamin
D contributes to maintain musculoskeletal health in healthy subjects as well as in patients with chronic kidney disease (CKD),
who display the combination of bone metabolism disorder, muscle wasting, and weakness. Here, we review how vitamin D
represents a pathway in which bone and muscle may interact. In vitro studies have confirmed that the vitamin D receptor
is present on muscle, describing the mechanisms whereby vitamin D directly affects skeletal muscle. These include genomic
and non‐genomic (rapid) effects, regulating cellular differentiation and proliferation. Observational studies have shown that
circulating 25‐hydroxyvitamin D levels correlate with the clinical symptoms and muscle morphological changes observed in
CKD patients. Vitamin D deficiency has been linked to low bone formation rate and bone mineral density, with an increased
risk of skeletal fractures. The impact of low vitamin D status on skeletal muscle may also affect muscle metabolic pathways,
including its sensitivity to insulin. Although some interventional studies have shown that vitamin D may improve physical
performance and protect against the development of histological and radiological signs of hyperparathyroidism, evidence is
still insufficient to draw definitive conclusions.
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Introduction
Beyond the well‐described functions of vitamin D in mineral
bone metabolism and calcium–phosphate homeostasis, there
is growing evidence of its role on muscle health and
function.1–3 Vitamin D deficiency is common in patients with
chronic kidney disease (CKD),4 a population in whom muscle
wasting and weakness are also highly prevalent.5–7
Observational studies have shown that circulating 25‐
hydroxyvitamin D [25(OH)D] levels are reduced in parallel to
the severity ofmuscle symptoms.8 Similarly, emerging evidence
suggests that vitamin D receptor (VDR) is expressed in muscle
and that VDR regulates gene expression and modulates the
uptake of 25(OH)D in skeletal muscle cells, which may also act
as a storage site for this vitamin D.9,10 There are also evidences
that hypovitaminosis D affects both contractilemuscle function
and muscle metabolism via disturbing insulin sensitivity.11
These observations collectively imply an integrated role of
vitamin D for bone and muscle health. Such a role may have
substantial clinical implications, especially for CKD patients, in
which musculoskeletal alterations and their complications,
including muscle pain and weakness, sarcopenia, fatigability,
reduced exercise tolerance, fractures, and falls, adversely affect
quality of life and survival.12–17
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In this review, we discuss the bidirectional actions of
vitamin D in bone and muscle, arguing on the potential
benefits of vitamin D supplementation as a strategy to tackle
the musculoskeletal problems of patients with CKD.
Vitamin D physiology
Vitamin D and bone‐mineral homeostasis
Natural (frequently referred as well as ‘native’) vitamin D is
produced at the skin following sunshine exposure and is not
totally required from the diet. The difference between
natural vitamin D2 and vitamin D3 lies on their origin
(vegetal or animal) and on the structure of their side
chains.18 Vitamin D is absorbed through the proximal
segments of the small intestine.19 As a hydrophobic
molecule, vitamin D circulates in the bloodstream mostly
(88–90%) bound with high affinity to the vitamin D binding
protein (DBP). Less than 0.05% of calcidiol [25(OH)D or
calcifediol] circulates free in plasma. To become fully active,
vitamin D needs to be transformed twice.20 A first
hydroxylation occurs in the liver microsomes by the 25‐
hydroxylase (CYP2R1) enzyme to form 25(OH)D. There is a
second hydroxylation in the proximal tubule by the
1α‐hydroxylase (CYP27B1) to form 1,25‐dihydroxyvitamin D
[1,25(OH)2D], also called calcitriol. In contrast to liver
hydroxylation, renal hydroxylation is highly regulated by
several factors including calcium, phosphate, parathyroid
hormone (PTH), and fibroblast growth factor 23 (FGF23),
which is produced by osteocytes and osteoblasts in bone.21
There is a feedback loop between FGF23 and vitamin D,
whereby FGF23 inhibits 1α‐hydroxylase activity and
stimulates 24,25‐hydroxylase, and simultaneously vitamin D
stimulates FGF23 production, which can still exacerbate the
high circulating FGF23 levels already existing in CKD and
impact bone metabolism.21,22 Indirect effects of FGF23
include the increase of renal excretion of phosphate,
affecting the amount of phosphate available for
mineralization at the bone surfaces.23 Direct effects of
FGF23 on bone metabolism include the modulation of bone
mineralization via the tissue non‐specific alkaline
phosphatase through the fibroblast growth factor receptor
3. FGF23 inhibits tissue non‐specific alkaline phosphatase,
and consequently, FGF23 increases extracellular
concentration of pyrophosphate, reduces the amount of
inorganic phosphate, and indirectly stimulates osteopontin
gene expression, a known mineralization inhibitor.24
1,25(OH)2D that passes into the bloodstream is also bound
to DBP, binding to the VDR in several tissues, including
parathyroid cells, bone, and intestine.25,26 The
VDR‐1,25(OH)2D complex acts as heterodimer with the
retinoic X receptor (RXR) to control transcriptional activity
of target genes, after binding to special DNA sequences called
vitamin D response elements. Circulating 1,25(OH)2D also
exerts non‐genomic effects through the binding in some
tissues to membrane proteins with subsequent modification
of the intra‐cellular calcium flux and stimulation of tyrosine
kinases (Figure 1).20,27,28 As a result of these processes, 1,25
(OH)2D maintains calcium and phosphate homeostasis,
stimulating their intestinal absorption and bone resorption.29
To accomplish this, the 1,25(OH)2D‐VDR‐RXR complex binds to
the vitamin D response elements in the small intestinal cells,
increasing the expression of the epithelial calcium channel.
It permits more calcium to enter the cell, which is translocated
into the circulation, ensuring the availability of sufficient
calcium and phosphate for adequate mineralization of the
newly formed bone matrix to avoid rickets/osteomalacia.
1,25(OH)2D induces skeletal anabolism and couples the
activity of osteoblasts and osteoclasts through the regulation
of several genes including osteopontin, osteocalcin, and the
Wnt receptor LRP5.30,31 Indeed, vitamin D stimulates the
expression of LRP5, which, together with sclerostin, Dkk1,
and frizzled, constitutes the Wnt pathway, a critical process
for skeletal mineralization that is tissue specific. Unlike in
bone, Vitamin D inhibits Wnt signals in the vessels and the
kidney, ameliorating the effect of Wnt activation on the
vascular calcification and kidney progression.32,33
Besides this anabolic effect on bone, direct effects of
vitamin D in osteoblasts may have the opposite effect,
stimulating bone resorption through osteoclastogenesis to
increase bone calcium mobilization.34 To do this, Vitamin D
interacts with the VDR in osteoblasts to induce the
expression of the plasma membrane protein receptor
activator of NF‐κB ligand (RANKL). The RANK on the plasma
membrane of preosteoclasts binds RANKL, which induces
the maturation of preosteoclasts to osteoclasts. The mature
osteoclast releases collagenases and hydrochloric acid to
dissolve bone and release its calcium and phosphate stores
into the bloodstream. Therefore, the ‘classical’ physiologic
function of vitamin D is to maintain blood levels of calcium
and phosphate within the normal physiologic range to
support most metabolic functions, neuromuscular
transmission, and bone mineralization.35
The VDR is also present in other tissues (including skeletal
muscle) that are not involved in mineral and bone
metabolism, where 1,25(OH)2D can locally be produced in
an auto‐paracrine or paracrine way (Figure 1), what results
in the so‐called ‘non‐classical’ vitamin D effects. Table 1
summarizes the main functions of vitamin D.29,36
Vitamin D and skeletal muscle weakness
In addition to the endocrine effects on calcium homeostasis
that are essential for muscle function, in vitro and in vivo
studies, along with changes in muscle morphology and
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metabolism observed in subjects with hypovitaminosis D,
have allowed the elucidation of novel pathways by which
vitamin D might act directly on skeletal muscle. These include
genomic and non‐genomic (rapid) effects (Figure 2).37,38
Genomic effects are delayed and include the gene expression
of contractile proteins and myogenic transcription factors
Figure 1 Vitamin D receptor (VDR)‐mediated actions of vitamin D: genomic and non‐genomic (rapid response) cellular signalling. 1,25(OH)2D interacts
with caveolae‐associated VDR to activate second messengers systems, including protein kinase C, phosphatidylinositol phosphate kinase,
phospholipase C, or opening of the voltage‐gated chloride channels or calcium channels, to generate non‐genomic responses. In the genomic pathway,
1,25(OH)2D associates with the retinoic acid receptor (RXR) and the trimeric complex (1,25(OH)2D‐VDR‐RXR) binds to the DNA in special sites called
‘vitamin D responsive elements’ (VDRE) to stimulate or inhibit the transcription of various genes. 1,25(OH)2D can locally be produced in an auto‐
paracrine or paracrine way.
Table 1 Effects and functions of vitamin D
Endocrine effects Non‐calcaemic and non‐skeletal effects
1. Increase intestinal absorption of calcium and phosphate
2. Down‐regulate expression of PTH mRNA in the parathyroid glands
3. Induce mature osteoclastic activity, which releases calcium
and phosphate into the bloodstream
↓
‘Classical’ functions
To maintain normal blood levels of calcium and
phosphate in order to support:
1. Bone mineralization
2. Metabolic functions
3. Neuromuscular function
1. Maintain normal cell proliferation and
differentiation.
2. Decrease renal production of renin
3. Stimulate pancreatic production of insulin
4. Immunomodulation
↓
‘Non‐classical’ functions
To modulate human health by metabolic imprinting
during the pre‐natal and neo‐natal periods that may
influence chronic disease susceptibility to cancer,
autoimmune, and cardiovascular diseases, soon after
birth as well as later in life.
mRNA, messenger ribonucleic acid; PTH, parathyroid hormone.
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after interacting vitamin D with the VDR in skeletal muscle
cells, which regulate muscle development and metabolism.
Several studies confirm that VDR is expressed in muscle
cells.9,39 Although VDR is expressed at low levels in resting
adult muscle, markedly VDR expression and 1α‐hydroxylase
have been observed in neonatal muscle or following muscle
injury, supporting the muscle capacity for local production
of 1,25(OH)2D, and a developmental and regenerative role
for vitamin D in this tissue.36,40,41
Vitamin D may also interact with the VDR in muscle cells
by non‐genomic effects, which are independent of the intra‐
nuclear transcription process. They involve the rapid
regulation of membrane calcium channels, suggesting a role
for vitamin D in the calcium‐mediated muscle functions,
such as muscle contraction and mitochondrial function,
which leads to an adequate insulin signalling and muscle
substrate metabolism.42 All these findings may clarify the
relationship between low vitamin D status and muscle
weakness,37,43 intramuscular fat deposition,44 and resistance
to insulin,45 which is related to cardiovascular risk and
increased skeletal muscle breakdown.46 Of note, skeletal
muscle may also act as a storage site for vitamin D, as
recently described.10
In addition to changes in muscle metabolic pathways, the
impact of vitamin D deficiency on skeletal muscle also
concerns muscle morphology. Subjects with mutations of
the VDR or severe vitamin D deficiency show generalized
muscle atrophy, even before biochemical signs of bone
disease appear.36,47 Changes in muscle morphology include
derangement of the intermyofibrillar network, increases in
intramuscular lipids, and atrophy of the fast‐twitch white
(type 2) fibres,11,44,48,49 which are the first to be recruited
when preventing a fall. All these changes seem to be
reversible,50 supporting co‐ordinated effects of vitamin D in
musculoskeletal physiology.51–54
Integrated pathway of the vitamin D, bone, and
muscle interplay
It is well known that sarcopenia and osteopenia occur
simultaneously in vitamin D‐deficient patients, whereas
muscle weakness and falls have been associated to vitamin D
deficiency are suggested as responsible for the high fracture
rate in this population.37,40,55 Observational data have
revealed that 25(OH)D levels predict the decline in bone
mineralization and physical performance when 25(OH)D falls
below 8 and 20 ng/mL (20 and 50 nmol/L), respectively.8,56
Although the underlying mechanisms remain to be elucidated,
vitamin Dmay represent a pathway by which bone andmuscle
may work together, enabling cross‐talk between these tissues
(Figure 3).1,37,57 In vitro studies have reported that vitamin D
Figure 2 Plausible effects of vitamin D on muscle cells. Adapted from Girgis et al.35
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reduces myostatin in cultured muscle cells, a hormone
released from the muscle that inhibits muscle growth.58,59 A
reduction in myostatin levels is also associated with increases
in bone mass.60 Vitamin D stimulates the muscle production
of vascular endothelial growth factor and insulin‐like growth
factor‐1 (IGF‐1), which are involved in muscle regeneration
after injury, as well as in bone growth and density.61–63 This
may explain how the administration of vitamin D improves
the recovery of skeletal muscle strength due to intense
exercise.64 1,25(OH)2D also brings the expression of
osteoglycin, another bone anabolic factor that is produced by
muscle tissues.65
Potential bone factors that affect muscle metabolism and
are regulated by vitamin D include sclerostin, osteocalcin,
and FGF23.1 Sclerostin is secreted by mature osteocytes,
inhibiting the Wnt signalling pathway that leads to
decreased bone formation and increased muscle
differentiation.66 Osteocalcin is a hormone produced by
osteoblasts that reduces sensitivity to insulin and enhances
the exercise capacity.67,68 FGF23 induces hypertrophy at
least on cardiac muscle, although its effects on skeletal
muscle are not fully understood.69 In addition, the effect
of vitamin D on decreasing serum levels of PTH may
positively affect muscle function, given that PTH induces
proteolysis and reduces creatine phosphate and inorganic
phosphate in muscle cell.70
Vitamin D metabolism in chronic
kidney disease
The kidney is the main site for conversion of 25(OH)D to
circulating 1,25(OH)2D. Although decreased 1,25(OH)2D
synthesis has been classically related to CKD, the circulating
concentration of both metabolites, 25(OH)D and
1,25(OH)2D, begins to decrease from the earliest stages of
CKD.71 Several factors are associated to this phenomenon
including reduced renal mass, dietary restrictions and
nutritional deficiencies, reduced sunlight exposure, skin
hyperpigmentation, diabetes mellitus, obesity, accumulation
of uremic toxins, impaired skin synthesis of cholecalciferol,
proteinuria, and increased FGF23.72,73 In addition, vitamin D
is transported in conjugation with DBP and filtered through
the glomerulus. Tubular reabsorption of vitamin D bound to
DBP is facilitated by the multi‐ligand receptor megalin.74 In
proteinuric CKD subjects, megalin is occupied by an extensive
albumin load, and therefore fewer receptors are available to
uptake 25(OH)D‐DBP, which contributes to vitamin D
deficiency.75
In addition to 25(OH)D, 1,25(OH)2D levels are also
reduced in CKD.4 Renal 1α‐hydroxylase activity reduces
as the renal mass decreases. Other down‐regulating
factors that are present in CKD patients include low
availability of 25(OH)D, hyperphosphatemia, metabolic
acidosis, and uraemia itself. Additionally, elevated FGF23
activates the enzyme 24‐hydroxylase (CYP24),
hydroxylating both 25(OH)D and 1,25(OH)2D. 24‐
hydroxylase limits the amount of 1,25(OH)2D in target
tissues both by producing 24,25(OH)2D (thus decreasing
the availability of 25(OH)D for 1 hydroxylation) or by
accelerating the catabolism of 1,25(OH)2D to
1,24,25(OH)3D resulting in calcitroic acid, which is
biologically inactive.76,77 CKD is also considered as a state
of vitamin D resistance, because VDR expression in bone
cells and in nodular parathyroid glands is reduced.78 Low
1,25(OH)2D levels also impair its binding to the VDR‐RXR
complex.79,80 The role of VDR and its interaction with
Figure 3 Integrative bone‐muscle‐cross‐talk mediated by vitamin D. Adapted from Girgis et al.38
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DNA has been comprehensively reviewed recently from
regular physiology to the systemic effects of CKD.25
The combination of vitamin D and/or 1,25(OH)2D
insufficiency and end‐organ resistance to vitamin D
contribute to the development of CKD‐MBD. Additional
mechanisms include the impairment of vitamin D‐
dependent osteocalcin production81 and the altered Wnt
signalling in osteoblasts and osteocytes observed in CKD,82
which is associated with bone loss and vascular
calcification.83,84 As vitamin D inhibits the adverse
TGFβ/Smad action on bone cells, a normal vitamin D status
might provide protection against Wnt signalling‐related
bone loss in CKD.85
Bone and musculoskeletal
abnormalities in chronic kidney disease
patients
Alteration of bone mass in chronic kidney disease
Patients with CKD exhibit considerable skeletal fragility,
which results from the large spectrum of CKD‐related bone
diseases, in addition to a variety of other factors including
age‐related osteoporosis and a significant number of non‐
specific therapeutic approaches directly affecting bone
metabolism such as the use of glucocorticosteroids, intestinal
phosphate binders, vitamin D compounds, bisphosphonates,
and calcimimetics. The measurement of bone mineral density
(BMD) is the usual method to assess bone quantity in these
patients. However, the assessment of bone quality is
uncommon and difficult, involving others factors such as
remodelling rate, bone geometry, and the extracellular matrix
properties.86
In addition, in CKD, the relation between BMD values,
fragility of bone, and fracture risk is not always so clear.
Bone loss is site specific, predominating at the mid‐radius,
with a greater loss of cortical rather than cancellous, which
is related to hyperparathyroidism, as opposite to the post‐
menopausal osteoporosis where the loss is mainly due to
cancellous bone from the axial skeleton.87 Moreover, CKD
patients show different patterns of bone loss. Whereas
some patients have a minimal bone loss, others show rapid
bone losses.86 Additionally, the presence of aorta
calcification and spinal osteoarthritis may bias BMD
measurement,88 being the hip and the radius better sites
for the BMD assessment. Interestingly, it has been shown
in a population of 2754 elderly subjects, including 587
subjects with CKD, that lower BMD was a risk factor
associated with skeletal fractures.89 Several other recent
papers have shown that low BMD actually predicts fracture
in dialysis and renal transplant patients.90,91 The use of
micro‐computerized tomography might also be a useful tool
for the estimation of bone loss and micro‐architectural
changes; however, they need further evaluation in CKD.92
Overall, although there have been uncertainties concerning
the utility of BMD in CKD,93 BMD measure may become
useful in this population. This issue is currently under
review,94 and it is likely that BMD testing could be
suggested in CKD patients with evidence of CKD‐MBD
and/or risk factors for osteoporosis, if results may affect
treatment decisions.95,96
Although bone histomorphometry is not routinely
recommended or executed in uremic patients, it is the gold
standard and the only way to evaluate the type of renal
osteodystrophy in CKD‐MBD.97,98 The bone histologic findings
in CKD range from low to high bone turnover, mineralization
troubles, and changes in bone volume. Each of these
histological patterns can appear isolated or co‐exist; and
none of them can be properly discriminated by using imaging
tools or circulating bone biomarkers. It must be stressed here
that because the prevalence of renal osteodystrophy in CKD‐
MBD is high, the presence of osteoporosis is often a diagnosis
of exclusion. In spite of this, the KDIGO working group
recommended to use in CKD the same World Health
Organisation osteoporosis definition applied to the general
population. It defines osteoporosis as a bone disorder
resulting in decreased bone strength and increased risk of
fracture, which is a broad definition that can be appropriately
used for diagnostic and management purposes at least in CKD
stages 1 to 4.
Alterations of muscle in chronic kidney disease
Severity and prevalence of myopathy in CKD develops already
at an eGFR <25 mL/min/1.73 m2 and increases concurrently
with the decline in GFR, concerning to more than half of
dialysis patients.99–101 The diagnosis of uremic myopathy is
based on clinical features, including weakness (defined as a
failure to generate force) and wasting (sarcopenia), which
affect predominantly the proximal lower limbs.102 Whereas
muscle enzymes levels and electromyographical studies are
usually normal, muscle biopsies show atrophy of the fast‐
twitch white (type 2) fibres.103,104 These morphological
features are similar from those found in patients with vitamin
D deficiency.11,48
The aetiology of uremic myopathy is multifactorial
(Table 2), including physical inactivity, reduced protein
intake, vitamin D deficiency, hyperparathyroidism,
metabolic acidosis, electrolyte disorder, low serum levels
of testosterone, resistance to growth hormone and insulin,
accumulation of uremic toxins, and carnitine deficiency,
which can lead to mitochondrial dysfunction.105,106
Observational studies have shown an inverse correlation
between muscle mass and blood levels of IL‐6 and C
reactive protein in CKD patients,12,107,108 postulating
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inflammation as an additional cause of muscle wasting in
this population.109–111 Although the process by which
inflammation produces sarcopenia has not yet been
identified, several mechanisms have been described,
including activation of NF‐κβ and angiotensin II
pathways,112–114 and the ATP‐dependent ubiquitin–
proteasome system, which has been identified as the most
important pathway for muscle wasting.115 Excellent reviews
on muscle wasting and dysfunction in patients with CKD
have been recently published.102,106
Vitamin D status in chronic kidney
disease: data from observational
studies
Vitamin D status, bone mineral density, and
fractures
A limited number of studies have looked at the relationship
between 25(OH)D levels and bone histology, BMD, and
fractures in CKD patients (Table 3). An observational study
of 104 dialysis patients who underwent a trans‐iliac bone
biopsy showed that patients with vitamin D insufficiency
[25(OH)D ≤ 15 ng/mL] had lower trabecular mineralization
Table 2 Causes of muscle wasting in chronic kidney disease
1. Physical inactivity
2. Reduced protein intake
3. Protein‐energy wasting
4. Hormonal disorders:
‐Vitamin D deficiency
‐Low testosterone
‐Hyperparathyroidism
‐Resistance to growth hormone
‐Resistance to insulin
‐Increased Angiotensin II
5. Metabolic disorders:
‐Metabolic acidosis
‐Electrolyte disorder
‐Uremic toxins accumulation
6. Inflammation
7. Myostatin overexpression
8. Low carnitine
Table 3 Studies investigating the association between circulating 25(OH)D levels and skeletal outcomes in chronic kidney disease patients
Reference Year N CKD stage Study design Outcome Results
Coen et al.116 2005 104 HD Retrospective Renal osteodystrophy
assessed by transiliac
bone biopsy
A mineralization defect and high bone
turnover was found with serum
25(OH)D < 15–20 ng/mL
Serum 25(OH)D > 40 ng/mL were
accompanied by a reduction of bone
turnover.
The optimal circulating level of 25(OH)D
appeared to be between 20 and 40 ng/mL
Ambrus et al.117 2011 130 HD Cross‐sectional Bone densitometry of
the lumbar spine,
femoral neck, and
distal radius
Patients with low‐trauma fractures
(n = 21) had lower serum 25(OH)D levels
(6.3 ng/mL vs. 12.0; p = 0.029)
25(OH)D < 8 ng/mL was independently
associated with bone fractures [OR 11.2
(95% CI: 1.3–94.8); p = 0.026]
Elder et al.118 2006 242 Stage 5 CKD
(5D, 85%
Cross‐sectional Prevalent spinal fracture
assessed by X‐ray and
BMD by DXA
25(OH)D correlated positively with Z‐
scores of BMD at the lumbar spine
(r = 0.24, p = 0.0005), femoral neck
(r = 0.23, p < 0.001), and wrist (r = 0.22,
p < 0.01).
Mucsi et al.119 2005 69 HD Cross‐sectional Bone densitometry and
quantitative bone
ultrasound
25(OH)D concentration was positively
correlated with BMD measured at the
radius (r = 0.424, p < 0.01) and with
attenuation on quantitative bone
ultrasound (beta = 0.262, P < 0.05).
Ghazali et al.120 1999 113 HD Cross‐sectional X‐rays of the hands
and pelvis were obtained
for evaluation of
sub‐periosteal resorption
and Looser’s zones
25(OH)D was significantly lower in the
groups with isolated sub‐periosteal
resorption (17.6 vs. 22.8 ng/mL; p < 0.05)
and with the combination of resorption
with Looser’s zones (10.4 vs. 22.8 ng/mL;
p < 0.004) than in the normal X‐ray
group.
Brunerová et al.121 2016 59 HD Cross‐sectional Bone densitometry,
including trabecular
bone score
Similar T‐scores and trabecular bone
scores among patients according to their
serum 25(OH)D levels
CKD, chronic kidney disease; HD, haemodialysis.
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surface and bone formation rate regardless of levels of
1,25(OH)2D and PTH.
116 Other studies have shown that CKD
patients with low circulating 25(OH)D have an increased risk
of reduced BMD and of skeletal fractures,117–119 as well as
of radiologic features of secondary hyperparathyroidism.120
In contrast, a more recent study that included 59 dialysis
patients did not show significant differences in T‐scores and
trabecular bone scores among patients according to their
25(OH)D levels.121 This apparent discrepancy may be
explained by the currently available treatments for CKD‐
MBD disorders that could alter the classical pathologic
findings of the bones in CKD and their relation to 25(OH)D
levels. Collectively, it seems clear that low vitamin D status
is associated with osteomalacia and fractures, presumably
because of mineralization defects. However, the data are less
robust in CKD than in the general population.122 In addition,
the increased osteoclastic activity due to secondary
hyperparathyroidism also removes matrix and minerals,
exacerbating low bone mass and osteoporosis. It is the
combination of mineralization defect and low bone mass that
likely increases risk for fractures.123,124
Vitamin D status, falls, muscle mass, and muscle
function
Although several studies have described the association
between low 25(OH)D levels with lower muscle strength
and mass, increased body instability and falls, worse physical
performance and frailty in vitamin D‐deficient older
adults,125–127 only a few studies have been undertaken in
CKD patients (Table 4). Gordon et al.128 observed a
relationship between 1,25(OH)2D levels, and physical
performance and muscle size in non‐dialysis CKD patients.
Further, Zahed et al.129 showed that 25(OH)D levels were
positively associated with muscle strength of the lower
extremities in haemodialysis patients, suggesting altogether
a plausible role of vitamin D supplementation for improving
muscle health in this population.
Interventional studies on vitamin D for
improving musculoskeletal health in
chronic kidney disease
Effect of vitamin D supplementation on bone
mineral density, renal osteodystrophy, and
fractures in chronic kidney disease
Multiple randomized trials have been conducted to examine
the effect of active vitamin Dmetabolites as well as nutritional
vitamin D supplements on bone biochemical markers in CKD
and end‐stage renal disease. Most of these studies have been
summarized in some meta‐analysis,130–132 demonstrating the
ability of vitamin D for lowering PTH, although treatment
was associated with clinical elevations in serum phosphate
and calcium. However, data are lacking in terms of patient‐
level skeletal outcomes such as fractures, BMD, bone pain,
or histomorphometric analysis of bone biopsies.133 Table 5
summarizes studies that investigated the impact of vitamin D
on skeletal health in CKD.134–142 Although vitamin D appeared
to protect against the development of histological evidence of
osteitis fibrosa and radiological signs of hyperparathyroidism,
most published studies have multiple methodological
limitations including small sample size and insufficient
follow‐up to appropriately ascertain these outcomes. To date,
no clear benefit on skeletal outcomes can be concluded from
the vitamin D administration in renal populations.133,143
Fortunately, a new meta‐analysis will conduct a systematic
review of nutritional vitamin D supplementation and health‐
related outcomes including fracture in end‐stage renal disease
patients.144
Table 4 Studies investigating the association between circulating 25(OH)D levels, muscle strength, and physical performance in chronic kidney disease
patients
Reference Year N CKD stage Study Design Outcome Results
Gordon et al.128 2012 26 CKD stage 3 or 4. Cross‐sectional Gait speed, 6 min walk, sit‐
to‐stand time, 1‐legged
balance, and thigh MCSA,
measured by MRI.
Serum 25(OH)D levels were
associated with normal gait speed
only (r = 0.41, P = 0.04).
Normal and fast gait speed, the
distance walked in 6 min, and sit‐
to‐stand time were best explained
by 1,25OH2D values.
Variance in MCSA was best
explained by a model containing
1,25OH2D values.
Zahed et al.129 2014 135 HD Cross‐sectional Muscle strength estimated
using a micro manual
muscle tester
Lower serum 25(OH)D levels were
observed in the group with less
muscle strength in lower
extremities
CKD, chronic kidney disease; HD, haemodialysis; MCSA, muscle cross‐sectional area; MRI, magnetic resonance imaging.
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Effect of vitamin D supplementation on risk of falls,
muscle mass and strength, and physical
performance in chronic kidney disease
Although extensive literature has shown that
supplementation with vitamin D in the general population
has a positive effect on skeletal muscle dysfunction including
falls, strength, and athletic performance,40,50,145,146 there is
not enough evidence to address the role of vitamin D on
musculoskeletal outcomes in CKD population.147
Musculoskeletal outcomes have not usually been considered
in most of existing trials. Although it may be argued that
intervention time was too short, in a recent randomized trial
providing oral cholecalciferol vs. placebo to haemodialysis
patients, no difference in the frequency of falls was noted
after 6 months.148 Similarly, only few small studies have
addressed the effect of vitamin D on muscle metabolic
pathways in renal population.149,150 Whereas in general
vitamin D does not seem to have any additional benefit on
glucose homeostasis and insulin sensitivity,151 repletion with
ergocalciferol may assist in improving glycaemic control in
CKD patients.150
Any vitamin D benefit on muscle strength is likely to occur
in patients with severe vitamin D deficiency. In an
interventional study that included both non‐dialysis CKD
stage 3–4 and peritoneal dialysis patients with severe vitamin
D deficiency [mean 25(OH)D < 7 ng/mL (17.5 nmol/L)],
vitamin D supplementation was found to improve physical
performance significantly, evaluated by the time to up and
go test, gait speed test, the timed chair stand test, and the
stair climb test.152 However, no definite conclusions can be
yet drawn from this emerging evidence and the question of
whether vitamin D supplementation is effective for muscle
outcomes remains unanswered.
Controversies in the definition of
vitamin D insufficiency in chronic
kidney disease
The optimal levels of 25(OH)D and the definition of vitamin D
insufficiency remain controversial both for the general
population and for patients with CKD.153,154 Whereas KDIGO
and the US Society of Endocrinology favour maintaining
25(OH)D levels between 30 to 50 ng/mL (75 to
125 nmol/L),154,155 the Institute of Medicine and the World
Health Organisation favour the range 20 to 40 ng/mL (50 to
100 nmol/L).156,157 Differences in these recommended target
ranges are attributed to controversies regarding 25(OH)D
intestinal calcium absorption, maximal suppression of PTH,
or optimal levels to prevent a clinical end‐point such as
fracture or death:
• Adequate intestinal calcium absorption. The adequate
25(OH)D levels to guarantee sufficient substrate for its
conversion to 1,25(OH)2D and ensure optimal calcium
absorption has been estimated to be >4.4 ng/mL
(11 nmol/L).158 However, this definition may be unsuitable
for CKD patients, in whom calcium absorption and
1,25(OH)2D production are impaired.
159
• Maximal suppression of PTH. Based on the inflexion point
at which PTH secretion is suppressed to a minimum in its
relation to 25(OH)D levels in the general population,160
KDIGO guidelines suggest to maintain serum 25(OH)D
levels >30 ng/mL (75 nmol/L) in CKD patients.154 Other
experts, however, estimate that 25(OH)D > 20 ng/mL
(50 nmol/L) are adequate to suppress PTH.157 Although
there is also an inverse relationship between 25(OH)D
and PTH levels in CKD patients,161,162 this
pathophysiological definition is possibly inappropriate in
these patients, given that PTH secretion is influenced by
several factors related to the uremic state (such as
hypocalcaemia or hyperphosphatemia), independently of
25(OH)D levels.163
• Fracture prevention. In non‐CKD population, vitamin D
supplementation to achieve the 25(OH)D target
concentration of 28 to 40 ng/mL (70 to 100 nmol/L)
lowered fracture risk.164–166 However, cross‐sectional
studies do not agree on the 25(OH)D threshold level
needed to maximize BMD and even suggest that BMD
may not improve with vitamin D supplementation once
baseline levels of 25(OH)D are >20 ng/mL.153 Moreover,
chronic 25(OH)D levels >40 ng/mL (100 nmol/L) after a
single annual dose of 500 000 IU of cholecalciferol
increased the risk of fractures.167 Interventional data
are lacking in CKD patients, and the optimal 25(OH)D
concentration for fracture risk reduction may only be
inferred from observational studies.133 In a small
cross‐sectional study including 130 patients on
haemodialysis, 25(OH)D < 8 ng/mL (20 nmol/L) was
independently associated with increased risk for bone
fractures.117
• Death prevention. Observational studies in both dialysis
and non‐dialysis patients have examined the prognostic
value of 25(OH)D levels. Wolf et al. showed that among
incident haemodialysis patients, those with 25(OH)D
levels < 10 ng/mL (25 nmol/L) were at increased risk of
90 day mortality, compared with subjects with 25(OH)
D > 30 ng/mL (75 nmol/L). The risk for cardiovascular‐
related mortality was also higher for patients with
25(OH)D between 10 to 30 ng/mL (25 to 75 nmol/L).168
Similar data have been reported for non‐dialysis patients
in two prospective studies of small sample size.169,170 We
have recently examined the prognostic value of 25(OH)D
levels among 470 non‐dialysis 3–5 stage CKD patients,
and observed consistent associations between 25(OH)D
levels and the risk of death, kidney progression, and
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hospitalization, with the respective concentrations of
17.4 ng/mL (43.4 nmol/L), 18.6 ng/mL (46.4 nmol/L), and
19.0 ng/mL (47.4 nmol/L), denoting the highest risk
prediction sensitivity and specificity.171
There are currently insufficient data to determine the
safe upper limit of serum 25(OH)D.153 Although the safety
margin to minimize the risk of hypercalcaemia as 25(OH)D
equal to 100 ng/mL (250 nmol/L), there are some concerns
at serum 25(OH)D levels above 50 ng/mL (125 nmol/L).
These concerns are based upon conflicting observational
studies describing an increased risk for fractures, ischaemic
cardiopathy, and some cancers, with levels above 30 to
48 ng/mL (75 to 120 nmol/L).167,172–175 Based on a recent
analysis from the 2007–2010 National Health and Nutrition
Examination Survey, proposals for lowering the cut‐off for
vitamin D deficiency to 12.5 ng/mL (31.2 nmol/L) have
emerged.176 CKD patients may be at special risk of
overscreening and overtreatment of vitamin D, and vitamin
D excess may be also a risk contributor for vascular
calcifications.177
Using randomized clinical trials from the general
population as the main guideline, we conclude that levels
below 20 ng/mL (50 nmol/L) are likely suboptimal for skeletal
health, which is in agreement with current experts’
recommendations.154–157 The recommendation of targeting
25(OH)D levels of 30 ng/mL (75 nmol/L) may be beneficial
for skeletal and extraskeletal health in CKD patients, but we
acknowledge that this statement is based on observational
studies and warrants consensus and confirmation.153
Although future trials will guide us to determine the optimal
25(OH) levels for dialysis patients, currently available data
suggest that vitamin D administration may confer a survival
benefit.178
Conclusion
In addition to control bone metabolism and calcium
homeostasis, growing evidence suggests that vitamin D
plays a key role for muscle function and metabolism in
health and CKD. Mechanistically, vitamin D exerts both
genomic and rapid effects on bone and muscle
metabolism. Furthermore, vitamin D may represent a
pathway by which bone and muscle may work together,
enabling cross‐talk between these tissues. Observational
studies have shown that CKD patients with vitamin D
deficiency have an increased risk of reduced BMD and
of skeletal fractures, presumably due to mineralization
defects, although the evidence is less strong in CKD than
in the general population. Likewise, the clinical symptoms
and muscle morphological changes observed in CKD
patients correlate with 25(OH)D levels, similarly to that
observed in subjects with hypovitaminosis D of other
origin. Lastly, although some interventional studies have
shown that vitamin D supplementation may improve
physical performance and bone health in CKD patients,
the limited evidence does not allow a certain conclusion
about the definitive role of vitamin D supplementation
on musculoskeletal outcomes in this population. However,
this lack of evidence does not necessarily indicate that
vitamin D supplementation has no effect on
musculoskeletal health. Moreover, given that vitamin D
supplementations is safe and cost‐effective, it can be
considered to improve muscle strength and physical
performance in CKD patients, especially those who have
25(OH)D levels below 20 ng/mL (50 nmol/L).
Acknowledgements
The European Renal Nutrition (ERN) and the Chronic Kidney
Disease‐Mineral and Bone Disorder (CKD‐MBD) working
groups are initiatives of and supported by the European
Renal Association‐European Dialysis Transplant Association
(ERA‐EDTA). The authors thank to the website http://www.
free‐anatomy‐quiz.com/ for sharing free images used on the
figures of this article.
The following are the board members of the ERN
working group: Denis Fouque (France); Juan J Carrero
(Sweden); Daniel Teta (Switzerland); Vincenzo Bellizi
(Italy); Christoph Wanner (Germany); Peter Ter Wee
(Netherlands); Siren Sezer (Turkey); Lina Johansson (United
Kingdom); Philippe Chauveau (France); and Pablo Molina
(Spain).
The following are the board members of the CKD‐MBD
working group: Mario Cozzolino (Italy); Marc Vervloet
(Netherlands); Vincent Brandenburg (Germany); Jordi Bover
(Spain); Adrian Covic (Romania); Pieter Evenepoel
(Belgium); David Goldsmith (United Kingdom); Ziad Massy
(France); Sandro Mazzaferro (Italy); and Pablo Ureña‐Torres
(France).
The authors of this manuscript certify that they comply
with the ethical guidelines for authorship and publishing in
the Journal of Cachexia, Sarcopenia and Muscle.179
Conflict of interest
P.M. has received speaking honoraria from Vifor‐Pharma‐
Fresenius Medical Care and Abbott Nutrition. J.J.C. has
received speaking honoraria from Abbott Nutrition and
Baxter Healthcare; institutional grants from AstraZeneca and
Vifor‐Pharma. J.B. has received speaking honoraria from
Abbvie, Amgen, and Shire; fees as a consultant for Abbvie,
Amgen, Vifor/Fresenius‐Pharma, Chugai, Medice,
Vitamin D, a modulator of musculoskeletal health 11
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12218
Genzyme/Sanofi, and Sanifit. P.C. acknowledges speaker
honoraria from Fresenius Kabi and Vifor Pharma. S.M. has
received speaker honoraria from Abbvie and Amgen. P.U.T.
has received personal fees and grants from Abbie, Amgen,
Astellas, Genzyme‐Sanofi, Hemotech, and Vifor‐Pharma‐
Fresenius Medical Care.
References
1. Gunton JE, Girgis CM, Baldock PA, Lips P.
Bone muscle interactions and vitamin D.
Bone 2015;80:89–94.
2. Halfon M, Phan O, Teta D. Vitamin D: a
review on its effects on muscle strength,
the risk of fall, and frailty. Biomed Res
Int 2015;2015:953241.
3. Tanner SB, Harwell SA. More than healthy
bones: a review of vitamin D in muscle
health. Ther Adv Musculoskelet Dis
2015;7:152–159.
4. Górriz JL, Molina P, Bover J, et al.
Characteristics of bone mineral
metabolism in patients with stage 3‐5
chronic kidney disease not on dialysis:
results of the OSERCE study. Nefrologia
2013;33:46–60.
5. Kittiskulnam P, Carrero JJ, Chertow GM,
Kaysen GA, Delgado C, Johansen KL.
Sarcopenia among patients receiving
hemodialysis: weighing the evidence. J
Cachexia Sarcopenia Muscle 2016.
https://doi.org/10.1002/jcsm.12130.
6. Kalantar‐Zadeh K, Rhee C, Sim JJ, Stenvinkel
P, Anker SD, Kovesdy CP. Why cachexia
kills: examining the causality of poor
outcomes in wasting conditions. J Cachexia
Sarcopenia Muscle 2013;4:89–94.
7. Mak RH, Ikizler AT, Kovesdy CP, Raj DS,
Stenvinkel P, Kalantar‐Zadeh K. Wasting
in chronic kidney disease. J Cachexia
Sarcopenia Muscle 2011;2:9–25.
8. Wicherts IS, van Schoor NM, Boeke AJ,
et al. Vitamin D status predicts physical
performance and its decline in older
persons. J Clin Endocrinol Metab
2007;92:2058–2065.
9. Girgis CM, Mokbel N, Cha KM, et al. The
vitamin D receptor (VDR) is expressed in
skeletal muscle of male mice and
modulates 25‐hydroxyvitamin D (25OHD)
uptake in myofibers. Endocrinology
2014;155:3227–3237.
10. Abboud M, Puglisi DA, Davies BN, et al.
Evidence for a specific uptake and
retention mechanism for 25‐
hydroxyvitamin D (25OHD) in skeletal
muscle cells. Endocrinology 2013;
154:3022–3030.
11. Ceglia L. Vitamin D and its role in skeletal
muscle. Curr Opin Clin Nutr Metab Care
2009;12:628–633.
12. Carrero JJ, Chmielewski M, Axelsson J, et al.
Muscle atrophy, inflammation and clinical
outcome in incident and prevalent dialysis
patients. Clin Nutr 2008;27:557–564.
13. Isoyama N, Qureshi AR, Avesani CM, et al.
Comparative associations of muscle mass
and muscle strength with mortality in
dialysis patients. Clin J Am Soc Nephrol
2014;9:1720–1728.
14. Kutner NG, Zhang R, Huang Y, Painter P.
Gait speed and mortality, hospitalization,
and functional status change among
hemodialysis patients: a US Renal Data
System special study. Am J Kidney Dis
2015;66:297–304.
15. Stenvinkel P, Carrero JJ, vonWalden F, Ikizler
TA, Nader GA. Muscle wasting in end‐stage
renal disease promulgates premature
death: established, emerging and potential
novel treatment strategies. Nephrol Dial
Transplant 2016;31:1070–1077.
16. Mak RH, Ikizler AT, Kovesdy CP, Raj DS,
Stenvinkel P, Kalantar‐Zadeh K. Wasting
in chronic kidney disease. J Cachexia
Sarcopenia Muscle 2011;2:9–25.
17. Carrero JJ, Stenvinkel P, Cuppari L, et al.
Etiology of the protein‐energy wasting
syndrome in chronic kidney disease: a
consensus statement from the
International Society of Renal Nutrition
and Metabolism (ISRNM). J Ren Nutr
2013;23:77–90.
18. Bikle DD. Vitamin D metabolism,
mechanism of action, and clinical
applications. Chem Biol 2014;21:319–329.
19. Lo CW, Paris PW, Clemens TL, Nolan J,
Holick MF. Vitamin D absorption in
healthy subjects and in patients with
intestinal malabsorption syndromes. Am
J Clin Nutr 1985;42:644–649.
20. Holick MF. Vitamin D deficiency. N Engl J
Med 2007;357:266–281.
21. Jüppner H. Phosphate and FGF‐23. Kidney
Int Suppl 2011;121:S24–S27.
22. Kolek OI, Hines ER, Jones MD, et al.
1alpha,25‐Dihydroxyvitamin D3
upregulates FGF23 gene expression in
bone: the final link in a renal‐
gastrointestinal‐skeletal axis that controls
phosphate transport. Am J Physiol
Gastrointest Liver Physiol 2005;289:
G1036–G1042.
23. Prié D, Ureña Torres P, Friedlander G.
Latest findings in phosphate homeostasis.
Kidney Int 2009;75:882–889.
24. Murali SK, Roschger P, Zeitz U, Klaushofer K,
Andrukhova O, Erben RG. FGF23 regulates
bone mineralization in a 1,25(OH)2 D3 and
Klotho‐independent manner. J Bone Miner
Res 2016;31:129–142.
25. Bover J, Ruiz CE, DaSilva M, Diaz M,
Guillen E. In Urena Torres P, Cozzolino
M, Vervloet, eds. Vitamin D receptor
and interaction with DNA: from
physiology to chronic kidney disease.
Vitamin D in Chronic Kidney Disease:
Cham, Switzerland: Springer; 2016.
26. Haussler MR, Whitfield GK, Haussler CA,
Hsieh JC, Jurutka PW. Nuclear Vitamin D
Receptor: Natural Ligands, Molecular
Structure‐Function, and Transcriptional
Control of Vital Genes. In David Felman
JW Pike, Adams JS, eds. Vitamin D. San
Diego, CA: Elsevier; 2011. p137–169.
27. Souberbielle JC, Body JJ, Lappe JM, et al.
Vitamin D and musculoskeletal health,
cardiovascular disease, autoimmunity and
cancer: recommendations for clinical
practice. Autoimmun Rev 2010;9:709–715.
28. Haussler MR, Jurutka PW, Mizwicki M,
Norman AW. Vitamin D receptor (VDR)‐
mediated actions of 1α,25(OH)₂vitamin
D₃: genomic and non‐genomic
mechanisms. Best Pract Res Clin
Endocrinol Metab 2011;25:543–559.
29. Holick MF. Resurrection of vitamin D
deficiency and rickets. J Clin Invest
2006;116:2062–2072.
30. Panda DK, Miao D, Bolivar I, et al.
Inactivation of the 25‐hydroxyvitamin D
1alpha‐hydroxylase and vitamin D
receptor demonstrates independent and
interdependent effects of calcium and
vitamin D on skeletal and mineral
homeostasis. J Biol Chem
200416;279:16754–16766.
31. Goltzman D. Use of genetically modified
mice to examine the skeletal anabolic
activity of vitamin D. J Steroid Biochem
Mol Biol 2007;103:587–591.
32. He W, Kang YS, Dai C, Liu Y. Blockade of
Wnt/β‐catenin signaling by paricalcitol
ameliorates proteinuria and kidney injury.
J Am Soc Nephrol 2011;22:90–103.
33. Al‐Aly Z. Arterial calcification: a tumor
necrosis factor‐alpha mediated vascular
Wnt‐opathy. Transl Res 2008;151:233–239.
34. Haussler MR,Whitfield GK, Kaneko I, et al.
Molecular mechanisms of vitamin D
action. Calcif Tissue Int 2013;92:77–98.
35. Holick MF. Vitamin D: importance in the
prevention of cancers, type 1 diabetes,
heart disease, and osteoporosis. Am J Clin
Nutr 2004;79:362–371.
36. Kaludjerovic J, Vieth R. Relationship
between vitamin D during perinatal
development and health. J Midwifery
Womens Health 2010;55:550–560.
37. Girgis CM, Clifton‐Bligh RJ, Hamrick MW,
Holick MF, Gunton JE. The roles of vitamin
D in skeletal muscle: form, function, and
metabolism. Endocr Rev 2013;34:33–83.
38. Hamilton B. Vitamin D and human
skeletal muscle. Scand J Med Sci Sports
2010;20:182–190.
39. Ceglia L, Harris SS. Vitamin D and its role
in skeletal muscle. Calcif Tissue Int
2013;92:151–162.
40. Girgis CM, Clifton‐Bligh RJ, Turner N, Lau
SL, Gunton JE. Effects of vitamin D in
skeletal muscle: falls, strength, athletic
12 P. Molina et al.
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12218
performance and insulin sensitivity. Clin
Endocrinol (Oxf) 2014;80:169–181.
41. Srikuea R, Zhang X, Park‐Sarge OK, Esser
KA. VDR and CYP27B1 are expressed in
C2C12 cells and regenerating skeletal
muscle: potential role in suppression of
myoblast proliferation. Am J Physiol Cell
Physiol 2012;303:C396–C405.
42. Sinha A, Hollingsworth KG, Ball S,
Cheetham T. Improving the vitamin D
status of vitamin D deficient adults is
associated with improved mitochondrial
oxidative function in skeletal muscle. J Clin
Endocrinol Metab 2013;98:E509–E513.
43. Floyd M, Ayyar DR, Barwick DD, Hudgson
P, Weightman D. Myopathy in chronic
renal failure. Q J Med 1974;43:509–524.
44. Gilsanz V, Kremer A, Mo AO, Wren TA,
Kremer R. Vitamin D status and its
relation to muscle mass and muscle fat
in young women. J Clin Endocrinol Metab
2010;95:1595–1601.
45. Gagnon C, Lu ZX, Magliano DJ, et al. Serum
25‐hydroxyvitamin D, calcium intake, and
risk of type 2 diabetes after 5 years: results
from a national, population‐based
prospective study (the Australian Diabetes,
Obesity and Lifestyle study). Diabetes Care
2011;34:1133–1138.
46. Siew ED, Pupim LB, Majchrzak KM,
Shintani A, Flakoll PJ, Ikizler TA. Insulin
resistance is associated with skeletal
muscle protein breakdown in non‐
diabetic chronic hemodialysis patients.
Kidney Int 2007;71:146–152.
47. Glerup H, Mikkelsen K, Poulsen L, et al.
Hypovitaminosis D myopathy without
biochemical signs of osteomalacic bone
involvement. Calcif Tissue Int
2000;66:419–424.
48. Yoshikawa S, Nakamura T, Tanabe H,
Imamura T. Osteomalacic myopathy.
Endocrinol Jpn 1979;26:65–72.
49. Tagliafico AS, Ameri P, Bovio M, et al.
Relationship between fatty degeneration
of thigh muscles and vitamin D status in
the elderly: a preliminary MRI study. AJR
Am J Roentgenol 2010;194:728–734.
50. Ceglia L, Niramitmahapanya S, da Silva
MM, et al. A randomized study on the
effect of vitamin D₃ supplementation on
skeletal muscle morphology and vitamin
D receptor concentration in older
women. J Clin Endocrinol Metab
2013;98:E1927–E1935.
51. Sørensen OH, Lund B, Saltin B, et al.
Myopathy in bone loss of ageing:
improvement by treatment with 1 alpha‐
hydroxycholecalciferol and calcium. Clin
Sci (Lond) 1979;56:157–161.
52. Sato Y, Iwamoto J, Kanoko T, Satoh K.
Low‐dose vitamin D prevents muscular
atrophy and reduces falls and hip
fractures in women after stroke: a
randomized controlled trial. Cerebrovasc
Dis 2005;20:187–192.
53. Cipriani C, Pepe J, Piemonte S, Colangelo
L, Cilli M, Minisola S. Vitamin d and its
relationship with obesity and muscle. Int
J Endocrinol 2014;2014:841248.
54. Wagatsuma A, Sakuma K. Vitamin D
signaling in myogenesis: potential for
treatment of sarcopenia. Biomed Res Int.
2014;2014:121254.
55. Visser M, Deeg DJ, Lips P. Longitudinal
Aging Study Amsterdam. Low vitamin D
and high parathyroid hormone levels as
determinants of loss of muscle strength
and muscle mass (sarcopenia): the
Longitudinal Aging Study Amsterdam. J
Clin Endocrinol Metab
2003;88:5766–5772.
56. Need AG, O’Loughlin PD, Morris HA,
Coates PS, Horowitz M, Nordin BE.
Vitamin D metabolites and calcium
absorption in severe vitamin D deficiency.
J Bone Miner Res 2008;23:1859–1863.
57. Kawao N, Kaji H. Interactions between
muscle tissues and bone metabolism. J
Cell Biochem 2015;116:687–695.
58. Garcia LA, King KK, Ferrini MG, Norris KC,
Artaza JN. 1,25(OH)2vitamin D3 stimulates
myogenic differentiation by inhibiting cell
proliferation and modulating the
expression of promyogenic growth factors
and myostatin in C2C12 skeletal muscle
cells. Endocrinology 2011;152:2976–2986.
59. White TA, LeBrasseur NK. Myostatin and
sarcopenia: opportunities and challenges
‐ a mini‐review. Gerontology
2014;60:289–293.
60. Elkasrawy MN, Hamrick MW. Myostatin
(GDF‐8) as a key factor linking muscle
mass and bone structure. J Musculoskelet
Neuronal Interact 2010;10:56–63.
61. Garcia LA, Ferrini MG, Norris KC, Artaza
JN. 1,25(OH)(2)vitamin D(3) enhances
myogenic differentiation by modulating
the expression of key angiogenic growth
factors and angiogenic inhibitors in C(2)C
(12) skeletal muscle cells. J Steroid
Biochem Mol Biol 2013;133:1–11.
62. Yakar S, Rosen CJ, Beamer WG, et al.
Circulating levels of IGF‐1 directly
regulate bone growth and density. J Clin
Invest 2002;110:771–781.
63. Street J, Bao M, deGuzman L, et al.
Vascular endothelial growth factor
stimulates bone repair by promoting
angiogenesis and bone turnover. Proc
Natl Acad Sci U S A 2002;99(15):9656–61.
64. Barker T, Schneider ED, Dixon BM,
Henriksen VT, Weaver LK. Supplemental
vitamin D enhances the recovery in peak
isometric force shortly after intense
exercise. Nutr Metab (Lond) 2013;10:69.
65. Tanaka K, Kanazawa I, Yamaguchi T, Yano
S, Kaji H, Sugimoto T. Active vitamin D
possesses beneficial effects on the
interaction between muscle and bone.
Biochem Biophys Res Commun
2014;450:482–487.
66. Kaji H. Interaction between muscle and
bone. J Bone Metab 2014;21:29–40.
67. Ferron M, McKee MD, Levine RL, Ducy P,
Karsenty G. Intermittent injections of
osteocalcin improve glucose metabolism
and prevent type 2 diabetes in mice. Bone
2012;50:568–575.
68. Mera P, Laue K, Ferron M, et al.
Osteocalcin signaling in myofibers is
necessary and sufficient for optimum
adaptation to exercise. Cell Metab
2016;23:1078–1092.
69. Faul C, Amaral AP, Oskouei B, et al. FGF23
induces left ventricular hypertrophy. J Clin
Invest 2011;121:4393–4408.
70. Haroon M, FitzGerald O. Vitamin D
deficiency: subclinical and clinical
consequences on musculoskeletal health.
Curr Rheumatol Rep 2012;14:286–293.
71. Moranne O, Froissart M, Rossert J, et al.
Timing of onset of CKD‐related metabolic
complications. J Am Soc Nephrol
2009;20:164–171.
72. Jacob AI, Sallman A, Santiz Z, Hollis BW.
Defective photoproduction of
cholecalciferol in normal and uremic
humans. J Nutr 1984;114:1313–1319.
73. Ureña‐Torres P, Metzger M, Haymann JP,
et al. Association of kidney function,
vitamin D deficiency, and circulating
markers of mineral and bone disorders
in CKD. Am J Kidney Dis 2011;
58:544–553.
74. Christensen EI, Willnow TE. Essential role
of megalin in renal proximal tubule for
vitamin homeostasis. J Am Soc Nephrol
1999;10:2224–2236.
75. Sato KA, Gray RW, Lemann J Jr. Urinary
excretion of 25‐hydroxyvitamin D in
health and the nephrotic syndrome. J
Lab Clin Med 1982;99:325–330.
76. Christakos S, Ajibade DV, Dhawan P,
Fechner AJ, Mady LJ. Vitamin D:
metabolism. Endocrinol Metab Clin North
Am 2010;39:243–253.
77. Shimada T, Kakitani M, Yamazaki Y, et al.
Targeted ablation of Fgf23 demonstrates
an essential physiological role of FGF23
in phosphate and vitamin D metabolism.
J Clin Invest 2004;113:561–568.
78. Fukuda N, Tanaka H, Tominaga Y,
Fukagawa M, Kurokawa K, Seino Y.
Decreased 1,25‐dihydroxyvitamin D3
receptor density is associated with a
more severe form of parathyroid
hyperplasia in chronic uremic patients. J
Clin Invest 1993;92:1436–1443.
79. Hsu CH, Patel SR. Altered vitamin D
metabolism and receptor interaction with
the target genes in renal failure: calcitriol
receptor interaction with its target gene
in renal failure. Curr Opin Nephrol
Hypertens 1995;4:302–306.
80. Patel SR, Ke HQ, Vanholder R, Koenig RJ,
Hsu CH. Inhibition of calcitriol receptor
binding to vitamin D response elements
by uremic toxins. J Clin Invest
1995;96:50–59.
81. Oury F, Sumara G, Sumara O, et al.
Endocrine regulation of male fertility by
the skeleton. Cell 2011;144:796–809.
82. Cejka D, Herberth J, Branscum AJ, et al.
Sclerostin and Dickkopf‐1 in renal
osteodystrophy. Clin J Am Soc Nephrol
2011;6:877–882.
83. Sabbagh Y, Graciolli FG, O’Brien S, et al.
Repression of osteocyte Wnt/β‐catenin
signaling is an early event in the
progression of renal osteodystrophy. J
Bone Miner Res 2012;27:1757–1772.
84. Evenepoel P, D’Haese P, Brandenburg V.
Sclerostin and DKK1: new players in renal
bone and vascular disease. Kidney Int
2015;88:235–240.
Vitamin D, a modulator of musculoskeletal health 13
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12218
85. Ding N, Yu RT, Subramaniam N, et al. A
vitamin D receptor/SMAD genomic circuit
gates hepatic fibrotic response. Cell
2013;153:601–613.
86. Ureña P, Bernard‐Poenaru O, Ostertag A,
et al. Bone mineral density, biochemical
markers and skeletal fractures in
haemodialysis patients. Nephrol Dial
Transplant 2003;18:2325–2331.
87. Riggs BL, Wahner HW, Seeman E, et al.
Changes in bone mineral density of the
proximal femur and spine with aging.
Differences between the postmenopausal
and senile osteoporosis syndromes. J Clin
Invest 1982;70:716–723.
88. Ott SM. Review article: bone density in
patients with chronic kidney disease
stages 4‐5. Nephrology (Carlton)
2009;14:395–403.
89. Yenchek RH, Ix JH, Shlipak MG, et al.
Health, aging, and body composition
study. Bone mineral density and fracture
risk in older individuals with CKD. Clin J
Am Soc Nephrol 2012;7:1130–1136.
90. Limori S, Mori Y, Akita W, et al. Diagnostic
usefulness of bone mineral density and
biochemical markers of bone turnover in
predicting fracture in CKD stage 5D
patients–a single‐center cohort study.
Nephrol Dial Transplant 2012;27:345–351.
91. Naylor KL, Leslie WD, Hodsman AB, Rush
DN, Garg AX. FRAX predicts fracture risk
in kidney transplant recipients.
Transplantation 2014;97:940–945.
92. Nickolas TL. The utility of circulating
markers to predict bone loss across the
CKD spectrum. Clin J Am Soc Nephrol
2014;9:1160–1162.
93. Miller PD. Bone disease in CKD: a focus on
osteoporosis diagnosis and management.
Am J Kidney Dis 2014;64:290–304.
94. www.kdigo.org
95. Ketteler M, Elder GJ, Evenepoel P, et al.
Revisiting KDIGO clinical practice
guideline on chronic kidney disease‐
mineral and bone disorder: a
commentary from a Kidney Disease:
Improving Global Outcomes
controversies conference. Kidney Int
2015;87:502–528.
96. Goldenstein PT, Jamal SA, Moysés RM.
Fractures in chronic kidney disease:
pursuing the best screening and
management. Curr Opin Nephrol
Hypertens 2015;24:317–323.
97. Moe S, Drüeke T, Cunningham J, et al.
Definition, evaluation, and classification
of renal osteodystrophy: a position
statement from Kidney Disease:
Improving Global Outcomes (KDIGO).
Kidney Int 2006;69:1945–1953.
98. Torres PU, Bover J, Mazzaferro S, de
Vernejoul MC, Cohen‐Solal M. When,
how, and why a bone biopsy should be
performed in patients with chronic
kidney disease. Semin Nephrol
2014;34:612–625.
99. Campistol JM. Uremic myopathy. Kidney
Int 2002;62:1901–1913.
100. Krishnan AV, Kiernan MC. Neurological
complications of chronic kidney disease.
Nat Rev Neurol 2009;5:542–551.
101. Patel SS, Molnar MZ, Tayek JA, et al.
Serum creatinine as a marker of muscle
mass in chronic kidney disease: results
of a cross‐sectional study and review of
literature. J Cachexia Sarcopenia Muscle
2013;4:19–29.
102. Fahal IH. Uraemic sarcopenia: aetiology
and implications. Nephrology Dialysis
Transplantation 2014;29:1655–1665.
103. Diesel W, Emms M, Knight BK, et al.
Morphologic features of the myopathy
associated with chronic renal failure. Am
J Kidney Dis 1993;22:677–684.
104. Fahal IH, Bell GM, Bone JM, Edwards RH.
Physiological abnormalities of skeletal
muscle in dialysis patients. Nephrol Dial
Transplant 1997;12:119–127.
105. Souza VA, Dd O, Mansur HN, Fernandes
NM, Bastos MG. Sarcopenia in chronic
kidney disease. J Bras Nefrol
2015;37:98–105.
106. Carrero JJ, Johansen KL, Lindholm B, et al.
Screening for muscle wasting and
dysfunction in patients with chronic
kidney disease. Kidney Int 2016;90:53–66.
107. Kaizu Y, Ohkawa S, Odamaki M, et al.
Association between inflammatory
mediators and muscle mass in long‐term
hemodialysis patients. Am J Kidney Dis
2003;42:295–302.
108. Isoyama N, Qureshi AR, Avesani CM, et al.
Comparative associations of muscle mass
and muscle strength with mortality in
dialysis patients. Clin J Am Soc Nephrol
2014;9:1720–1728.
109. Stenvinkel P, Alvestrand A. Inflammation
in end‐stage renal disease: sources,
consequences, and therapy. Semin Dial
2002;15:329–337.
110. Guttridge DC, Mayo MW, Madrid LV,
Wang CY, Baldwin AS Jr. NF‐kappaB‐
induced loss of MyoD messenger RNA:
possible role in muscle decay and
cachexia. Science 2000;289:2363–2366.
111. Carrero JJ, Stenvinkel P, Cuppari L, et al.
Etiology of the protein‐energy wasting
syndrome in chronic kidney disease: a
consensus statement from the
International Society of Renal Nutrition
and Metabolism (ISRNM). J Ren Nutr
2013;23:77–90.
112. Langen RC, Schols AM, Kelders MC,
Wouters EF, Janssen‐Heininger YM.
Inflammatory cytokines inhibit myogenic
differentiation through activation of
nuclear factor‐kappaB. FASEB J 2001;
15:1169–1180.
113. Mitch WE, Du J, Bailey JL, Price SR.
Mechanisms causing muscle proteolysis
in uremia: the influence of insulin and
cytokines. Miner Electrolyte Metab
1999;25:216–219.
114. Zhang L, Du J, Hu Z, et al. IL‐6 and serum
amyloid A synergy mediates angiotensin
II‐induced muscle wasting. J Am Soc
Nephrol 2009;20:604–612.
115. Mitch WE, Goldberg AL. Mechanisms of
muscle wasting. The role of the
ubiquitin‐proteasome pathway. N Engl J
Med 1996;335:1897–1905.
116. Coen G, Mantella D, Manni M, et al. 25‐
hydroxyvitamin D levels and bone
histomorphometry in hemodialysis renal
osteodystrophy. Kidney Int
2005;68:1840–1848.
117. Ambrus C, Almasi C, Berta K, et al.
Vitamin D insufficiency and bone
fractures in patients on maintenance
hemodialysis. Int Urol Nephrol
2011;43:475–482.
118. Elder GJ, Mackun K. 25‐Hydroxyvitamin D
deficiency and diabetes predict reduced
BMD in patients with chronic kidney
disease. J Bone Miner Res
2006;21:1778–1784.
119. Mucsi I, Almási C, Deák G, et al. Serum 25
(OH)‐vitamin D levels and bone
metabolism in patients on maintenance
hemodialysis. Clin Nephrol
2005;64:288–294.
120. Ghazali A, Fardellone P, Pruna A, et al. Is
low plasma 25‐(OH)vitamin D a major risk
factor for hyperparathyroidism and
Looser’s zones independent of calcitriol?
Kidney Int 1999;55:2169–2177.
121. Brunerová L, Ronová P, Verešová J, et al.
Osteoporosis and impaired trabecular
bone score in hemodialysis patients.
Kidney Blood Press Res 2016;41:345–354.
122. Moorthi RN, Moe SM. Recent advances in
the noninvasive diagnosis of renal
osteodystrophy. Kidney Int
2013;84:886–894.
123. Leonard MB. A structural approach to
skeletal fragility in chronic kidney disease.
Semin Nephrol 2009;29:133–143.
124. Malluche HH, Porter DS, Pienkowski D.
Evaluating bone quality in patients with
chronic kidney disease. Nat Rev Nephrol
2013;9:671–680.
125. Dhesi JK, Bearne LM, Moniz C, et al.
Neuromuscular and psychomotor
function in elderly subjects who fall and
the relationship with vitamin D status. J
Bone Miner Res 2002;17:891–897.
126. Janssen HC, Samson MM, Verhaar HJ.
Vitamin D deficiency, muscle function,
and falls in elderly people. Am J Clin Nutr
2002;75:611–615.
127. Ensrud KE, Blackwell TL, Cauley JA, et al.
Circulating 25‐hydroxyvitamin D levels
and frailty in older men: the osteoporotic
fractures in men study. J Am Geriatr Soc
2011;59:101–106.
128. Gordon PL, Doyle JW, Johansen KL.
Association of 1,25‐dihydroxyvitamin D
levels with physical performance and
thigh muscle cross‐sectional area in
chronic kidney disease stage 3 and 4. J
Ren Nutr 2012;22:423–433.
129. Zahed N, Chehrazi S, Falaknasi K. The
evaluation of relationship between
vitamin D and muscle power by micro
manual muscle tester in end‐stage renal
disease patients. Saudi J Kidney Dis
Transpl 2014;25:998–1003.
130. Palmer SC, McGregor DO, Macaskill P,
Craig JC, Elder GJ, Strippoli GF. Meta‐
analysis: vitamin D compounds in chronic
kidney disease. Ann Intern Med
2007;147:840–853.
131. Palmer SC, McGregor DO, Craig JC, Elder
G, Macaskill P, Strippoli GF. Vitamin D
compounds for people with chronic
14 P. Molina et al.
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12218
kidney disease requiring dialysis.
Cochrane Database Syst Rev 2009;4:
CD005633.
132. Kandula P, Dobre M, Schold JD,
Schreiber MJ Jr, Mehrotra R,
Navaneethan SD. Vitamin D
supplementation in chronic kidney
disease: a systematic review and meta‐
analysis of observational studies and
randomized controlled trials. Clin J Am
Soc Nephrol 2011;6:50–62.
133. Nigwekar SU, Tamez H, Thadhani RI.
Vitamin D and chronic kidney disease‐
mineral bone disease (CKD‐MBD).
Bonekey Rep 2014;3:498.
134. Fournier A, Bordier P, Gueris J, et al.
Comparison of 1 alpha‐
hydroxycholecalciferol and 25‐
hydroxycholecalciferol in the treatment
of renal osteodystrophy: greater effect
of 25‐hydroxycholecalciferol on bone
mineralization. Kidney Int
1979;15:196–204.
135. Memmos DE, Eastwood JB, Talner LB,
et al. Double‐blind trial of oral 1,25‐
dihydroxy vitamin D3 versus placebo in
asymptomatic hyperparathyroidism in
patients receiving maintenance
haemodialysis. Br Med J (Clin Res Ed)
1981;282:1919–1924.
136. Morinière P, Fournier A, Leflon A, et al.
Comparison of 1 alpha‐OH‐vitamin D3
and high doses of calcium carbonate for
the control of hyperparathyroidism and
hyperaluminemia in patients on
maintenance dialysis. Nephron
1985;39:309–315.
137. Baker LR, Muir JW, Sharman VL, et al.
Controlled trial of calcitriol in
hemodialysis patients. Clin Nephrol
1986;26:185–191.
138. Baker LR, Abrams L, Roe CJ, et al. 1,25
(OH)2D3 administration in moderate
renal failure: a prospective double‐blind
trial. Kidney Int 1989;35:661–669.
139. Llach F, Keshav G, Goldblat MV, et al.
Suppression of parathyroid hormone
secretion in hemodialysis patients by a
novel vitamin D analogue: 19‐nor‐1,25‐
dihydroxyvitamin D2. Am J Kidney Dis
1998;32:S48–S54.
140. Watson AR, Kooh SW, Tam CS, Reilly BJ,
Balfe JW, Vieth R. Renal osteodystrophy
in children on CAPD: a prospective trial
of 1‐alpha‐hydroxycholecalciferol therapy.
Child Nephrol Urol 1988‐1989;9:220–227.
141. Delmez JA, Kelber J, Norwood KY, Giles
KS, Slatopolsky E. A controlled trial of
the early treatment of secondary
hyperparathyroidism with calcitriol in
hemodialysis patients. Clin Nephrol
2000;54:301–308.
142. Mager DR, Jackson ST, Hoffmann MR,
Jindal K, Senior PA. Vitamin D3
supplementation, bone health and quality
of life in adults with diabetes and
chronickidney disease: Results of an open
label randomized clinical trial. Clin Nutr
2016; pii: S0261‐5614(16)30108‐X.
143. Theodoratou E, Tzoulaki I, Zgaga L,
Ioannidis JP. Vitamin D and multiple health
outcomes: umbrella review of systematic
reviews and meta‐analyses of
observational studies and randomised
trials. BMJ 2014;348:g2035.
144. Mehrotra A, Leung WY, Joson T.
Nutritional vitamin D supplementation
and health‐related outcomes in
hemodialysis patients: a protocol for a
systematic review and meta‐analysis. Syst
Rev 2015;4:13.
145. Murad MH, Elamin KB, Abu Elnour NO,
et al. Clinical review: the effect of vitamin
D on falls: a systematic review and meta‐
analysis. J Clin Endocrinol Metab
2011;96:2997–3006.
146. Morley JE, Argiles JM, Evans WJ, et al.
Nutritional recommendations for the
management of sarcopenia. J Am Med
Dir Assoc 2010;11:391–396.
147. Kalantar‐Zadeh K, Kovesdy CP. Clinical
outcomes with active versus nutritional
vitamin D compounds in chronic kidney
disease. Clin J Am Soc Nephrol
2009;4:1529–1539.
148. Miskulin DC, Majchrzak K, Tighiouart H,
et al. Ergocalciferol supplementation in
hemodialysis patients with vitamin d
deficiency: a randomized clinical trial. J
Am Soc Nephrol 2016;27:1801–1810.
149. de Boer IH, Sachs M, Hoofnagle AN, et al.
Paricalcitol does not improve glucose
metabolism in patients with stage 3‐4
chronic kidney disease. Kidney Int
2013;83:323–330.
150. Blair D, Byham‐Gray L, Lewis E, McCaffrey
S. Prevalence of vitamin D [25(OH)D]
deficiency and effects of supplementation
with ergocalciferol (vitamin D2) in stage 5
chronic kidney disease patients. J Ren
Nutr 2008;18:375–382.
151. Seida JC, Mitri J, Colmers IN, et al. Clinical
review: effect of vitamin D3
supplementation on improving glucose
homeostasis and preventing diabetes: a
systematic review and meta‐analysis. J
Clin Endocrinol Metab
2014;99:3551–3560.
152. Taskapan H, Baysal O, Karahan D, Durmus
B, Altay Z, Ulutas O. Vitamin D and muscle
strength, functional ability and balance in
peritoneal dialysis patients with vitamin D
deficiency. Clin Nephrol 2011;76:110–116.
153. Bouillon R, Van Schoor NM, Gielen E,
et al. Optimal vitamin D status: a critical
analysis on the basis of evidence‐based
medicine. J Clin Endocrinol Metab
2013;98:E1283–E1304.
154. Kidney Disease: Improving Global
Outcomes (KDIGO) CKD‐MBD Work
Group. KDIGO clinical practice guideline
for the diagnosis, evaluation, prevention,
and treatment of Chronic Kidney
Disease‐Mineral and Bone Disorder
(CKD‐MBD). Kidney Int Suppl 2009;
S1–130.
155. Holick MF, Binkley NC, Bischoff‐Ferrari
HA, et al. Evaluation, treatment, and
prevention of vitamin D deficiency: an
Endocrine Society clinical practice
guideline. J Clin Endocrinol Metab
2011;96:1911–1930.
156. Ross AC, Taylor CL, Yaktine AL, Del Valle
HB. Institute of Medicine (US) Committee
to Review Dietary Reference Intakes for
Vitamin D and Calcium: Dietary Reference
Intakes for Calcium and Vitamin D.
Washington (DC): National Academies
Press (US); 2011. Available from: http://
www.ncbi.nlm.nih.gov/books/NBK56070/.
157. WHO Scientific Group on the Prevention
and Management of Osteoporosis 2003
Prevention and management of
osteoporosis: report of a WHO scientific
group. Geneva: World Health
Organization. http://apps.who.int/iris/
bitstream/10665/42841/1/
WHO_TRS_921.pdf (last accessed on 26th
March 2017)
158. Need AG, O’Loughlin PD, Morris HA,
Coates PS, Horowitz M, Nordin BE.
Vitamin D metabolites and calcium
absorption in severe vitamin D
deficiency. J Bone Miner Res 2008;
23:1859–1863.
159. Spiegel DM, Brady K. Calcium balance in
normal individuals and in patients with
chronic kidney disease on low and high
calcium diets. Kidney Int
2012;81:1116–1122.
160. Vieth R, Ladak Y, Walfish PG. Age‐related
changes in the 25‐hydroxyvitamin D
versus parathyroid hormone relationship
suggest a different reason why older
adults require more vitamin D. J Clin
Endocrinol Metab 2003;88:185–191.
161. González EA, Sachdeva A, Oliver DA,
Martin KJ. Vitamin D insufficiency and
deficiency in chronic kidney disease. A
single center observational study. Am J
Nephrol 2004;24:503–510.
162. Molina P, Górriz JL, Molina MD, et al. The
effect of cholecalciferol for lowering
albuminuria in chronic kidney disease: a
prospective controlled study. Nephrol Dial
Transplant 2014;29:97–109.
163. Metzger M, Houillier P, Gauci C, et al.
Relation between circulating levels of 25
(OH) vitamin D and parathyroid hormone
in chronic kidney disease: quest for a
threshold. J Clin Endocrinol Metab
2013;98:2922–2928.
164. Dawson‐Hughes B, Harris SS, Krall EA,
Dallal GE. Effect of calcium and vitamin
D supplementation on bone density in
men and women 65 years of age or older.
N Engl J Med 1997;337:670–676.
165. Chapuy MC, Pamphile R, Paris E, et al.
Combined calcium and vitamin D3
supplementation in elderly women:
confirmation of reversal of secondary
hyperparathyroidism and hip fracture
risk: the Decalyos II study. Osteoporos
Int 2002;13:257–264.
166. Trivedi DP, Doll R, Khaw KT. Effect of
four monthly oral vitamin D3
(cholecalciferol) supplementation on
fractures and mortality in men and
women living in the community:
randomised double blind controlled trial.
BMJ 2003;326:469.
167. Sanders KM, Stuart AL, Williamson EJ,
et al. Annual high‐dose oral vitamin D
and falls and fractures in older women:
a randomized controlled trial. JAMA
2010;303:1815–1822.
Vitamin D, a modulator of musculoskeletal health 15
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12218
168. Wolf M, Shah A, Gutierrez O, et al.
Vitamin D levels and early mortality
among incident hemodialysis patients.
Kidney Int 2007;72:1004–1013.
169. Barreto DV, Barreto FC, Liabeuf S, et al.
Vitamin D affects survival independently
of vascular calcification in chronic kidney
disease. Clin J Am Soc Nephrol
2009;4:1128–1135.
170. Ravani P, Malberti F, Tripepi G, Pecchini P,
Cutrupi S, Pizzini P, Mallamaci F, Zoccali C.
Vitamin D levels and patient outcome in
chronic kidney disease. Kidney Int
2009;75:88–95.
171. Molina P, Górriz JL, Molina MD, et al.
What is the optimal level of vitamin D in
non‐dialysis chronic kidney disease
population? World J Nephrol
2016;5:471–481.
172. Dror Y, Giveon SM, Hoshen M, Feldhamer
I, Balicer RD, Feldman BS. Vitamin D levels
for preventing acute coronary syndrome
and mortality: evidence of a nonlinear
association. J Clin Endocrinol Metab
2013;98:2160–2167.
173. Stolzenberg‐Solomon RZ, Vieth R, Azad A,
et al. A prospective nested case‐control
study of vitamin D status and pancreatic
cancer risk in male smokers. Cancer Res
2006;66:10213–10219.
174. Stolzenberg‐Solomon RZ, Jacobs EJ, Arslan
AA, et al. Circulating 25‐hydroxyvitamin D
and risk of pancreatic cancer: Cohort
Consortium Vitamin D Pooling Project of
Rarer Cancers. Am J Epidemiol
2010;172:81–93.
175. Ahn J, Peters U, Albanes D, et al. Serum
vitamin D concentration and prostate
cancer risk: a nested case‐control study.
J Natl Cancer Inst 2008;100:796.
176. Manson JE, Brannon PM, Rosen CJ, Taylor
CL. Vitamin D deficiency ‐ is there really a
pandemic? N Engl J Med
2016;375:1817–1820.
177. Drüeke TB, Massy ZA. Role of vitamin D in
vascular calcification: bad guy or good
guy? Nephrol Dial Transplant
2012;27:1704–1707.
178. Cheng S, Coyne D. Vitamin D and
outcomes in chronic kidney disease. Curr
Opin Nephrol Hypertens 2007;16:77–82.
179. von Haehling S, Morley JE, Coats AJS,
Anker SD. Ethical guidelines for
authorship and publishing in the Journal
of Cachexia, Sarcopenia and Muscle J
Cachexia Sarcopenia Muscle.
2015;4:315–316.
16 P. Molina et al.
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12218
